Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Earwax MD** is a patented, over-the-counter topical ear drop formulation developed by Eosera, a Dallas-based biotechnology company, for the removal of excessive or impacted earwax (cerumen). It employs a proprietary **dual-action technology** that disrupts the lipid and wax components of earwax using sodium and potassium bicarbonates to convert hydrophobic fatty acids into hydrophilic forms, while glycolic acid loosens attached skin cells (keratinocytes) and debris; glycerin provides hyper-hydration to facilitate breakdown. Clinically proven in a study of 30 impacted ears to fully clear impaction in 86% of cases with 1-2 applications in 15-30 minutes and reduce symptoms (fullness, itching, hearing loss) by 82%, it outperforms competitors like Debrox and Murine in lab tests on human earwax disintegration. Safe for ages 2+, dermatologist-tested with no reported irritation, and available in kits with rinsing bulbs; made in the USA.[1][2][3][5][6]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Earwax MD.